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Abstract
Background
Despite availability of effective cure, tuberculosis (TB) remains a leading cause of death in
children. In many high-burden countries, childhood TB is underdiagnosed and underre-
ported, and care is often accessed too late, resulting in adverse treatment outcomes. In this
study, we examined the time to death and its associated factors among a cohort of children
that commenced TB treatment in a large treatment centre in northern Nigeria.
Methods
This is a retrospective cohort study of children that started TB treatment between 2010 and
2014. We determined mortality rates per 100 person-months of treatment, as well as across
treatment and calendar periods. We used Cox proportional hazards regression to determine
adjusted hazard ratios (aHR) for factors associated with mortality.
Results
Among 299 children with a median age 4 years and HIV prevalence of 33.4%; 85 (28.4%)
died after 1,383 months of follow-up. Overall mortality rate was 6.1 per 100 person-months.
Deaths occurred early during treatment and declined from 42.4 per 100 person-months in
the 1st week of treatment to 2.2 per 100 person-months after at the 3rd month of treatment.
Mortality was highest between October to December period (9.1 per 100 pm) and lowest
between July and September (2.8 per 100 pm). Risk factors for mortality included previous
TB treatment (aHR 2.04:95%CI;1.09–3.84); HIV infection (aHR 1.66:95%CI;1.02–2.71),
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having either extra-pulmonary disease (aHR 2.21:95%CI;1.26–3.89) or both pulmonary and
extrapulmonary disease (aHR 3.03:95%CI;1.70–5.40).
Conclusions
Mortality was high and occurred early during treatment in this cohort, likely indicative of poor
access to prompt TB diagnosis and treatment. A redoubling of efforts at improving universal
health coverage are required to achieve the End TB Strategy target of zero deaths from TB.
Introduction
Tuberculosis (TB) is a major and often unrecognised cause of morbidity and mortality in chil-
dren.[1] With an estimated 1 million new TB cases and over 200,000 deaths worldwide, chil-
dren accounted for 10% of new infections and 12.5% of deaths in 2015.[2] Childhood TB
represents recent and ongoing transmission and a potential reservoir from which the epidemic
can continue in the future. TB in children presents with particular challenges including diffi-
culties with bacteriologic confirmation, as sputum samples are often unobtainable with conse-
quent underreporting.[3–5] Furthermore older children, with adult-type disease contribute to
transmission.
Reducing mortality is an important target for TB control.[6] However, assessment of TB
mortality is challenging in many high TB-burden countries due to poor or absent vital registra-
tion systems. The World Health Organization (WHO) recommends the use of deaths among
persons with TB (case fatality) as an alternative approach to estimating TB-associated mortal-
ity.[2] Case fatality also assesses inequities in access to TB care.
In Nigeria, there were 586,000 new TB cases in 2015 with high levels of suboptimal out-
comes; the lowest TB treatment coverage (15%) and the highest case fatality (43%) among the
30 high TB-burden countries.[2] Outcomes in children may be worse in view of the poor
access to general health care. Based on national guidelines, TB cases as well as treatment out-
comes in children should be notified to the TB programme. However, due to poor reporting,
current data may not accurately reflect outcomes especially in subgroups where diagnosis may
be more challenging and risk of death higher. In this study, we analysed data from a large ter-
tiary hospital to examine levels of, and factors associated with, mortality among a cohort of
children that commenced TB treatment.
Materials and methods
Study design and data sources
This was a retrospective cohort study with data obtained from clinic-based registers for
patients at the Aminu Kano Teaching Hospital (AKTH). AKTH is a large tertiary hospital pro-
viding specialist services to a large catchment area comprising Kano metropolis and neigh-
bouring states and general medical services to the local population. Data on age, gender, urban
or rural residence, HIV status, disease site, prior TB treatment and treatment outcomes were
obtained from the registers.
Study population
Patients that enrolled in the clinic and commenced treatment between January 2010 and
December 2014 and were less than 15 years of age were included in this analysis. Patients
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come from a variety of sources and they include both out-patients and in-patients. These
sources comprise patients from other clinics from within the hospital including the paediatric
out-patient clinic and HIV clinic; patients referred from other clinics and hospitals within and
outside Kano; in-patients from the paediatric wards within the hospital. In our data, 83(27.8%)
were in-patients. Information on all subjects included in our analysis were from the TB clinic-
based registers because all patients with a TB diagnosis are registered in the clinic irrespective
of their source. For in-patients, the managing team collects the patient information and comes
to the register the patient in the clinic. Diagnosis and treatment were according to the Nigerian
National TB and Leprosy Control Programme guidelines. Diagnosis of TB is largely based on a
composite score comprising a combination of clinical and laboratory findings: unexplained
fever, chest radiography abnormalities, history of close contact with a smear-positive pulmo-
nary TB patient, undernutrition (assessed using weight-for-height), poor or non-response to
antibiotics, and tuberculin skin test (TST) induration size. Patients presenting with cough last-
ing for 2 weeks or more had sputum sent to the TB laboratory for bacteriologic confirmation
through smear microscopic examination. Sputum was obtained either by expectoration (from
children that could produce sputum) or gastric lavage. Chest X-rays were also obtained for
younger children and those unable to produce sputum if pulmonary tuberculosis was sus-
pected. Diagnosis of extra pulmonary tuberculosis (EPTB) was sometimes based on fine needle
aspiration cytology, histopathological examination, biochemical and microscopic analyses of
cerebrospinal/pleural/ascitic fluids.
Treatment for new cases of TB comprised two phases: a 2-month intensive phase with
Rifampicin, Isoniazid, Ethambutol and Pyrazinamide; and a 4 or 6-month continuation phase
with Rifampicin and Isoniazid. Prior to 2014, patients with history of TB treatment had
3-month intensive phase with Streptomycin injection added to the regimen. Paediatric drugs
are generally provided free under the State TB Control Programme. However, occasional
stock-outs occur and in such cases, appropriate doses are reconstituted from loose adult tablets
in the hospital drug manufacturing unit or patients are asked to obtain their drugs from pri-
vate pharmaceutical outlets.
Treatment outcome definitions
Treatment outcomes were defined using the WHO TB treatment outcome definitions.[7]
Death included loss of life from any cause after treatment commenced. Cure was defined as
smear- or culture-negative status in the last month of treatment in a patient who was bacterio-
logically confirmed at treatment onset. Treatment completion was defined as any patient who
completed treatment without evidence of failure and with no record of a negative smear or cul-
ture result in the last month of treatment, while treatment failure was defined as being sputum
or culture-positive at the 5th month of treatment. Treatment interruption for 2 consecutive
months or more was characterized as “loss to follow up”. Successful treatment included
patients categorised as “cured” or “treatment completed”.
Statistical analysis
All analyses were conducted using Stata 14 (Stata Corp, College Station, TX, USA). Cohort
entry was defined as the date of treatment initiation. All subjects were followed up until the
first to occur from the following dates: death; treatment failure; loss to follow-up; and treat-
ment completion. To determine mortality rates, follow-up time was set as time from treatment
initiation and expanded into person-months (pm). Mortality rates per 100pm were estimated.
Cox proportional hazard modelling was used to estimate hazard ratios (HR) for mortality. In
addition to age, we adjusted for covariates that were associated with mortality at univariable
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analysis with p<0.2 (gender, residence, HIV status, disease site, prior TB treatment and calen-
dar year).
We also determined timing of death in relation to treatment duration and calendar period.
To examine death in relation to treatment duration, follow-up time was split into weekly/
monthly intervals; and into the treatment phases (intensive and continuation). To examine
death in relation to calendar period, follow up time was set as calendar year and each year was
split into quarters.
Ethics
Ethical approval was obtained from the Research Ethics Committee of AKTH (NHREC/21/08/
2008/AKTH/EC/1562). Patient consent was not required by the ethics committee since data
were obtained retrospectively from patients’ records.
Results
Between 2010 and 2014, 312 children commenced TB treatment with 299 (95.8%) children
included in the analysis as 13 were excluded due to incomplete information on either treat-
ment outcome or date of treatment initiation. Children represented 21% of the 1,796 patients
enrolled in the clinic over the study period. The characteristics of the study population are
summarised in Table 1. There were more boys than girls with a male to female ratio of 1.34:1.
The age of participants ranged from 3 months to 14 years with a median (IQR) of 4 years (1.5–
9). One-third (33.4%) of the children were HIV-positive. Pulmonary disease was the most
common disease presentation (63.9%), while central nervous system disease accounted for
5.7% of all cases.
Treatment outcome
Distribution of treatment outcome over the study period is summarised in Table 2. About half
of the children (52.5%) had a successful treatment outcome. Overall, among children with
unsuccessful treatment outcomes, 85 (59.9%) died, 1 (0.7%) failed treatment and 56 (39.4%)
were lost to follow-up during treatment. The proportion of patients with successful treatment
outcome progressively increased from 17% in the 2010/2011 period to 65% in 2014. The pro-
portion lost to follow-up also declined from 29.3% in 2010/2011 to 11% in 2014.
Mortality rates
There were 85 deaths during a total follow-up time of 1383.3 months, with an overall mortality
rate of 6.1 per 100 person-months (95% CI: 5.0–7.6). Crude mortality rates across patient char-
acteristics are shown in Table 1. Mortality rates were similar across all age groups, but slightly
higher among boys (7.1/100pm: 95% CI 5.4–9.2) than girls (5.1/100pm; 95% CI: 3.6–7.2).
HIV-positive children also had a higher mortality (11.3/100pm; 95% CI: 8.3–15.3) than chil-
dren who were HIV-negative (4.3/100pm; 95%CI: 3.2–5.7) or had unknown HIV status (4.3/
100pm; 95% CI: 1.1–17.2). Mortality declined between 2010 and 2014. Crude analysis revealed
that compared to urban-dwelling children, those living in rural areas were 68% more likely to
die (95% CI: 1.09–2.58).
After adjusting for age, gender, residence, HIV status, history of prior TB treatment, disease
site and calendar period; being HIV-positive (aHR 1.66;95%CI:1.02–2.71); history of prior TB
treatment (aHR 2.04;95%CI:1.09–3.84); and having either extrapulmonary (aHR 2.21;95%
CI:1.26–3.89) or both extrapulmonary and pulmonary disease (aHR 3.03;95%CI:1.70–5.40)
were found to be independent risk factors for mortality in the study population (Table 3).
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Timing of deaths
The median survival time for patients that died was 14 days (IQR: 6–54 days). About a third
(35.3%) of the deaths occurred within the 1st week of treatment with a crude mortality of 42.4
(95% CI: 29.6–60.6) per 100 person-months in the 1st week of treatment. Mortality steadily
declined over the treatment period to 2.2 (95% CI: 1.4–3.6) per 100 person-months among
children that had been on treatment for 4 months or more. When treatment period was ana-
lysed by treatment phases, risk of mortality was nearly 8 times higher during intensive phase
compared to the continuation phase. This increased risk of death in the earlier periods of treat-
ment remained after adjusting for age, gender, residence, HIV status, history of prior TB treat-
ment, and disease site.
Table 1. Description of study cohort and mortality rates across explanatory variables, TB clinic, Aminu Kano Teaching Hospital, Kano, Nigeria.
Variable Total Number of deaths (%) Person-months Mortality rate per 100pm (95%CI)
Age group (years)
<5 152 44(29.0) 695.6 6.3(4.7–8.5)
5–9 80 22(27.5) 377.3 5.8(3.8–8.9)
 10 67 19(28.4) 310.4 6.1(3.9–9.6)
Gender
Male 171 53(31.0) 751 7.1(5.4–9.2)
Female 128 32(25.0) 632.3 5.1(3.6–7.2)
Residence
Urban 196 47(24.0) 956.5 4.9(3.7–6.5)
Rural 103 38(36.9) 426.8 8.9(6.5–12.2)
HIV status
Negative 189 43(21.6) 1011 4.3(3.2–5.7)
Positive 100 42(42.0) 372.3 11.3(8.3–15.3)
Unknown 10 2(20.0) 46.5 4.3(1.1–17.2)
Previous TB treatment
No 267 71(26.6) 1256.1 5.7(4.5–7.1)
Yes 32 14(43.8) 127.3 11.0(6.5–18.6)
Disease site
Pulmonary 191 40(20.9) 910.3 4.4(3.2–6.0)
Extrapulmonary 66 24(36.4) 306.9 7.8(5.2–11.7)
Both 42 21(50.0) 166.2 12.6(8.2–19.4)
Calendar year
2010–2011 58 31(53.5) 154.1 20.1(14.1–28.6)
2012 64 19(29.7) 283.9 6.7(4.3–10.5)
2013 106 19(17.9) 545.7 3.5(2.2–5.5)
2014 71 16(22.5) 399.6 4.0(2.5–6.5)
https://doi.org/10.1371/journal.pone.0183270.t001
Table 2. Treatment outcomes of children over study period, TB clinic, Aminu Kano Teaching Hospital, Kano, Nigeria.
Calendar year
Treatment outcome 2010–2011
n (%)
2012
n (%)
2013
n (%)
2014
n (%)
Total
n (%)
Successful treatment 10(17.2) 30(46.9) 71(67.0) 46(64.8) 157(52.5)
Died 31(53.5) 19(29.7) 19(17.9) 19(22.5) 85(28.4)
Lost to follow-up 17(29.3) 15(23.4) 16(15.1) 8(11.3) 56(18.7)
Failed treatment 0(0.0) 0(0.0) 0(0.0) 1(1.4) 1(0.3)
https://doi.org/10.1371/journal.pone.0183270.t002
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Analysis of timing death across calendar period showed that mortality was highest between
October and December period (9.1/100pm; 95% CI: 6.3–13.3), with more than twice the risk
of death compared to January to March period, on both crude and adjusted analyses (Table 4).
Discussion
This study demonstrates unacceptably poor outcomes with high mortality among children
during TB treatment in this large urban centre. Overall, over a quarter of the children that
started TB treatment died, and these deaths occurred early during treatment, with over three-
quarters of the deaths occurring in the intensive phase of treatment. We also show variation in
death rates over time. Deaths declined steadily over the study period suggesting improvement
in recent years, but varied within each study year. Our results also indicate that disease site and
history of prior TB treatment were independent risk factors for mortality.
Compared to other single-hospital studies, reported deaths were still lower than our find-
ings. In a referral hospital Peru, analysis of 25-year data of hospitalised children with TB
reported 11% mortality.[8] In Ethiopia, analysis of data from a rural hospital over 10 years
Table 3. Univariable and multivariable analyses of risk factors for mortality among children, TB clinic, Aminu Kano Teaching Hospital, Kano,
Nigeria.
Variable Number of deaths (%) Crude HR
(95% CI)
P value
(LRT)1
Adjusted HR
(95% CI)2
P value
(LRT)1
Age
<5 44(29.0) 0.98(0.57–1.68) 1.25(0.70–2.21)
5–9years 22(27.5) 0.94(0.51–1.74) 1.01(0.53–1.09)
10years+ 19(28.4) 1 0.98 1 0.65
Gender
Male 53(31.0) 1 1
Female 32(25.0) 0.74(0.47–1.15) 0.18 0.65(0.41–1.03) 0.07
Residence
Urban 47(24.0) 1 1
Rural 38(36.9) 1.68(1.09–2.58) 0.02 1.47(0.94–2.29) 0.1
HIV status
Negative 43(21.6) 1 1
Positive 42(42.0) 2.40(1.57–3.70) 0.0001 1.66(1.02–2.71)
Unknown 2(20.0) 0.96(0.23–3.98) 0.92(0.21–3.96) 0.11
Previous TB treatment
No 71(26.6) 1 1
Yes 14(43.8) 1.83(1.03–3.26) 0.05 2.04(1.09–3.84) 0.04
Disease site
Pulmonary 40(20.9) 1 1
Extrapulmonary 24(36.4) 1.78(1.07–2.96) 2.21(1.26–3.89)
Both 21(50.0) 2.71(1.60–4.60) 0.001 3.03(1.70–5.40) 0.0004
Calendar year
2010–2011 31(53.5) 1
2012 19(29.7) 0.38(0.22–0.68) 0.52(0.27–1.00)
2013 19(17.9) 0.22(0.12–0.38) 0.20(0.10–0.38)
2014 16(22.5) 0.25(0.14–0.470 <0.0001 0.25(0.13–0.50) <0.0001
1 Likelihood ratio test
2 Adjusted for all variables in the table
https://doi.org/10.1371/journal.pone.0183270.t003
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reported 3.9% deaths.[9] In the Democratic Republic of Congo, a 5-year retrospective analysis
of TB data from a tertiary-level health facility, reported only 1.4% deaths.[10] However, our
study population comprised a relatively younger (median age– 4 years) with a much higher
HIV prevalence.
As expected mortality during treatment is higher than reported in many studies using pro-
grammatic data from other high TB-burden populations.[11–15] In Lagos, southern Nigeria,
analysis of state-wide TB data showed that 6% of children died while on treatment.[15] In
Benin, a 2-year retrospective study reported 9% mortality.[11] In southern Ethiopia, analysis
of 5-year district-wide treatment outcome reported that 3% of the children died.[12] In
Malawi, a nation-wide survey of programme data in 1998 reported that 17% of the children
died; [13] while analysis of 3-year (2011–2013) programme data from treatment centres in
central Malawi reported 9.5% deaths.[14] Likely inclusion of more severe cases with higher
mortality risk, would at least in part explain the difference between these studies and our
findings.
The high and early mortality during treatment in this study could be attributable to many
factors. Delay in diagnosis could result in disease progression because of the difficulties in
diagnosis of childhood TB, especially if cough is absent, or sputum cannot be made for
Table 4. Timing of deaths among children on TB treatment, TB clinic, Aminu Kano Teaching Hospital, Kano, Nigeria.
Time since treatment
onset
Number of
deaths
Proportionate mortality
(%)
Person-
months
Mortality rate per 100pm
(95%CI)
Crude HR (95%
CI)
Adjusted HR (95%
CI)1
Time since treatment
onset
1st week 30 35.3 70.8 42.4(29.6–60.6) 18.34(8.65–
38.92)
17.66(8.10–38.49)
2nd week 18 21.2 63.1 28.5(18.0–45.3) 21.17(9.2–
48.47)
23.18(9.68–55.52)
3rd week 5 5.9 58.3 8.6(3.6–20.6) 4.93(1.58–
15.37)
4.80(1.49–15.46)
Fourth week 4 6.2 56.7 7.1(2.6–18.8) 4.30(1.32–
13.96)
3.57(1.05–12.11)
2nd month 8 9.4 212.3 3.8(1.9–7.5) 2.37(0.92–
6.13)
2.19(0.83–5.79)
3rd month 4 4.7 199.6 2.0(0.8–5.3) 1.04(0.92–
6.13)
0.92(0.28–2.99)
4th month+ 16 18.8 722.5 2.2(1.4–3.6) 1 1
Total 85 1383.3 6.1(5.0–7.6)
Treatment phase
Intensive phase 65 76.5 461.2 14.1(11.1–18.0) 7.86(4.21–
14.00)
7.89(4.38–14.20)
Continuation phase 20 23.5 922.1 2.2(1.4–3.4) 1 1
Calendar period
(season)
Jan-Mar 32 37.6 660.8 4.8(3.4–6.8) 1 1
Apr-Jun 10 11.8 147.5 6.8(3.6–12.6) 0.78(0.37–
1.56)
0.73(0.36–1.52)
Jul-Sept 16 18.8 279.9 2.8(3.5–9.3) 0.87(0.48–
1.60)
0.83(0.45–1.55)
Oct-Dec 27 31.8 295.1 9.1(6.3–13.3) 2.07(1.23–
3.46)
2.18(1.29–3.70)
1 adjusted for age, place of residence, gender, HIV status, disease site, and history of previous TB treatment
https://doi.org/10.1371/journal.pone.0183270.t004
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bacteriological examination, or in EPTB.[16] Due to these diagnostic challenges, lower-cadre
health care workers at primary care level where the majority of TB care is provided may fail to
suspect TB in children or may not have access to diagnostic equipment, such as radiographs.
[17] Because a number of patients were referred from other lower-level hospitals, it is possible
that lower cadre health care workers at this levels may face greater challenges in diagnosis of
TB in children and this may have contributed to overall delays in diagnosis and treatment ini-
tiation. Frequent drug stock-outs may also cause delayed treatment; and compromised adher-
ence; resulting in inadequate dosing from reconstituted adult drugs; or risked ingestion of
adulterated or expired drugs.[17] Treatment adherence may be poor in children and worsened
by epileptic drug supply, poor tolerance, and socio-economic factors.[18] Though microscopy
and drugs (when available) are provided free by the TB programme, transportation and other
diagnostic tests are out-of-pocket expenses which may negatively affect adherence and treat-
ment outcome.[19] High HIV-burden (a third were co-infected) in this cohort could also have
contributed to high mortality from delayed diagnosis; co-morbidities from other opportunistic
infections; and drug interactions potentially compromising adherence or effectiveness of anti-
TB drugs.[20–22] Drug-susceptibility testing only became available in 2014 in the centre,
therefore, undiagnosed drug resistant TB may also have contributed to high mortality, espe-
cially with previous history of TB treatment being a strong predictor of death.
The relatively high HIV co-infection in our cohort (33.4%) is similar to levels reported
from Lagos (29%), another highly populous state in Nigeria. [15] [23] Other states in the coun-
try reported much lower levels of coinfection. In Zaria, northern Nigeria, a hospital-based
study found coinfection levels of 9%. [24] A state-wide study in south-west Nigeria also
showed coinfection of 11%. [25] In AKTH coinfection among HIV-infected adults was 10.5%
[26] and 40% among TB patients [27]. In southern Africa, coinfection levels are higher ranging
from 42% to 56% [28–32]. While in other parts of sub-Saharan Africa coinfection levels are
lower than our findings. [33] [34] Though HIV prevalence in Kano state is relatively low, the
high level of coinfection in this cohort may be attributed to the fact the study site is one of the
largest HIV service providers in the state.
Though mortality did not vary with age, the relative young age of this cohort could have
accounted for the overall high mortality. Diagnosis is more challenging in younger children as
clinical features are not distinct to TB, but largely similar to other prevalent childhood dis-
eases.[35] An immature immune system in younger children results in disseminated disease,
which further complicates diagnosis, [15] [16] and increases the risk of disease progression.
[36] Additionally, higher prevalence of other co-morbidities which are prevalent in this popu-
lation, such as severe undernutrition, pneumonia and undiagnosed HIV infection contribute
to early deaths.[16]
Other studies have reported timing of deaths during treatment. In a 10-year hospital-based
study in Ethiopia, the mean survival time was low (10 days) in children despite overall low
mortality (3.9%).[9] In a retrospective analysis of data from two referral centres in South
Africa, median survival time was 112 days among hospitalised HIV-positive patients with high
levels of poor treatment response.[37] In India, a retrospective review of treatment outcome
showed consistent deaths throughout the treatment period, which is attributed to underesti-
mation of early deaths due to high default and poor treatment adherence in the cohort.[38]
The temporal trend in improvement of treatment success and reduction of mortality over
the study period (2010 to 2014) in our study could be attributed to expansion of TB services
including availability of paediatric drugs; expansion of HIV services including ART; and likely
maturity of the programme within the hospital and in the country at large.
Seasonal variation in mortality observed may reflect underlying burden of other childhood
diseases such as respiratory tract infections as well as TB incidence which in turn can increase
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the risk of death.[39, 40] In South Africa, an increase in hospitalisation from PTB and pneu-
mococcal disease after the influenza season was reported.[41] The presence of such co-morbid-
ities may also have led to overdiagnosis of TB and wrong treatment; and contributed to high
mortality in our cohort.[42] Pulmonary disease was the most common presentation in this
cohort, and majority of participants (77.9%) had either PTB alone or in combination with
EPTB. It is likely that other respiratory tract infections could have contributed to mortality in
our cohort.
Major strengths of this study include the availability of dates to allow time-to-event analysis,
and inclusion of patients that access TB drugs outside the TB programme.
This study relied on retrospective clinic registers and, therefore, includes only data reported
in the registers or patient treatment cards. Other important clinical data such as nutritional
status, use of isoniazid prophylaxis, BCG vaccination, anti-retroviral treatment, CD4 cell
count were either not available or missing from the registers. Socio-economic data such as
family income, parental education, which influence treatment-seeking are also unavailable
from these registers. The representativeness of our findings may be limited to similar tertiary-
level TB treatment centres. However, due to the diversity of the patients and the fact that the
diagnosis of smear-negative TB and EPTB in children often relies on paediatricians or pulmo-
nologists located at higher-level hospitals, our findings represent an important sub-group with
increased risk of poor outcome that may not be so apparent from programme-level data. Our
findings are likely to underestimate overall mortality, as we do not account for deaths before
diagnosis or treatment initiation; and deaths after treatment from relapse, treatment failure
or other TB sequelae.[37, 43] Though efforts are made to contact patients lost to follow-up
through the contact number of guardian provided to the clinic on enrolment before treatment
outcome is registered, it is possible that among patients that could not be reached, a number
of them could have died and this may have resulted in underestimation of mortality in this
cohort. Conversely, it is possible that some deaths included in our analysis may be unrelated to
TB. However, because vital registration is poor, analysis of TB treatment cohort such as this
one provides an insight into the quality of TB care in this subpopulation.
Conclusion
The high and early mortality of children on TB treatment points to significant inequities in
access to TB care. Diagnosis and treatment are delayed; and adherence may be poor, and these
lead to adverse treatment outcomes. These delays may be reflective of overall poor health care
access among this population. Temporal variations in mortality also suggest that background
incidence of other common childhood infections may be contributing to deaths in children.
Our findings point towards the importance of the End TB Strategy’s targets of universal health
coverage and social protection for ending TB by 2035.[44]
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